Company intelligence / Profile preview

Saguaro Biosciences

Quebec City, Quebec, Canadasaguarobio.com ↗

Ownership: Private
Development stage: Other

Overview

Saguaro Biosciences has developed ChromaLive™, a non-toxic, data-rich dye platform that enables high-content live-cell imaging without the need for wash steps. The technology is already adopted by over 150 biotech and pharmaceutical companies to enhance phenotypic screening and drug profiling. The company recently secured $3 million in seed funding to expand commercialization efforts. No clinical results as the company does not develop therapeutics.

Therapeutic areas: Other
Modalities: Reagent/Fluorescent Dye Platform
Industry: Non-Drug Biotech

Partnerships

Over 150 biotech/pharma companies use their dyes/products, but specific partnership names are undisclosed.

Beyond the preview

Go deeper on Saguaro Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saguaro Biosciences.

Explore the full profile